(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release
Posted in Business, Denmark, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharma, Board of Directors, CEO, Charl van Zyl, CNS, Deborah Dunsire, Eli Lilly, H. Lundbeck A/S, immunology, Lars Rasmussen, Lundbeck, Neurology, Novartis
(IN BRIEF) Roche has announced a collaboration with Eli Lilly to support the development of its Elecsys Amyloid Plasma Panel (EAPP) which is an innovative blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease. The EAPP test … Read the full press release
LONDON, 22-Dec-2016 — /EuropaWire/ — WPP announces that its wholly-owned operating company Grey Group, the global marketing communications company, has acquired Entreprise de Communications Tank Inc. (“Tank”), a leading full-service healthcare and consumer agency in Canada. Tank’s audited net revenues were … Read the full press release
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd tillsätts som vd för Becton, Dickinson and Companys (BD) affärsenhet BD Nordics. Helena har över 20 års erfarenhet som chef inom farmaceutisk och medicinteknisk verksamhet hos välkända aktörer inom branschen, bland annat ResMed, … Read the full press release
Posted in Denmark, Healthcare, Management, News, Technology, United Kingdom
Tagged BD, Becton Dickinson, Eli Lilly, Helena Bragd, Johnson and Johnson, Novartis, ResMed
OXFORD, 17-12-2015 — /EuropaWire/ — Helena Bragd has joined global medical technology leader Becton, Dickinson and Company (BD) as General Manager for the Nordic region. Helena brings more than 20 years of pharmaceutical- and med-tech leadership experience to the role, … Read the full press release
Posted in Healthcare, Management, News, Technology, United Kingdom
Tagged appointment, BD, Becton Dickinson, Eli Lilly, Healthcare, Helena Bragd, Johnson and Johnson, Medica Comms, medical technology, Novartis, ResMed
Ingelheim, Germany and Indianapolis, US, 24-8-2015 — /EuropaWire/ — Boehringer Ingelheim and Eli Lilly and Company today announced positive top-line results from EMPA-REG OUTCOME®. This is a long-term clinical trial investigating cardiovascular (CV) outcomes for Jardiance® (empagliflozin) in more than 7,000 … Read the full press release
Phase II/III trial of AZD3293, an oral potent small molecule inhibitor of BACE, aims to enrol more than 1,500 patients in 15 countries LONDON, 2-12-2014 — /EuropaWire/ — AstraZeneca and Eli Lilly and Company (Lilly) today announced enrolment of the … Read the full press release
Paris, France, 31-1-2014 — /EuropaWire/ — Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it filed a patent infringement suit against Eli Lilly and Company ( “Lilly”) on January 30, 2014 in the United States District Court for the District of Delaware. In … Read the full press release
Posted in France, Healthcare, Law, Pharma & Biotech
Tagged Eli Lilly, Lantus®, Lantus® SoloStar®, patent infringement suit, Sanofi
Ingelheim, Germany and Indianapolis, US, 1-7-2013 — /europawire.eu/ — Boehringer Ingelheim and Eli Lilly and Company today announced results from a new analysis of Phase III data demonstrating that treatment with the dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin is not associated with … Read the full press release
Posted in Business, Germany, Healthcare, Pharma & Biotech, Science
Tagged 73rd Scientific Sessions®, American Diabetes Association, Boehringer Ingelheim, Diabetes, dipeptidyl peptidase-4, DPP-4, Dr. Odd Erik Johansen, Eli Lilly, Germany, Indianapolis, Ingelheim, Linagliptin, T2D, type 2 diabetes, US
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?
PHARMA & BIOTECH: The largest repository of EU/European pharma & biotech press releases spanning 12 years (2012-2024)
